Hello Turtle,
I hope you're right, I sure would like to see news in the next couple of weeks.
Once they get this news out, I'd also like to learn if they're keeping track of patient weight as a secondary endpoint. I've heard rumors on the message boards, which in most cases is like dividing by zero; undefined and meaningless, that MRK dropped their MC-3/4 agonist program due to priapism. I doubt MRK would be that stupid, as the drug would still work in women and most of the overweight patients who want treatment are women, anyway. Nevertheless, it's clear the MC-4 receptor, in particular, regulates body weight and I'd like to see the weight changes of the patients in the bremelanotide trials, stratfied according to the number of doses used over the term of each trial.
Finally a correction, I noted in an earlier post that I wish ARNA would start their phase 3 safety study, but indeed they did start it a couple of weeks ago! The recent Oppenheimer presentation was particularly good, with a lot of new basic science data presented.
The new job is OK, but I have to use a PC instead of a Mac and it's painful....
RE42 |
